To liberate candidate gene analyses from criticisms of inexhaustiveness of examination of specific candidate genes, or incompleteness in the choice of candidate genes to study for specific neurobiological pathways, study of sizeable sets of genes pertinent to each putative pathophysiological pathway is required. For many years, genes have been tested in a 'one by one' manner for association with major affective disorders, primarily bipolar illness. However, it is conceivable that not individual genes but abnormalities in several genes within a system or in several neuronal, neural, or hormonal systems are implicated in the functional hypotheses for etiology of affective disorders. Compilation of candidate genes for entire pathways is a challenge, but can reasonably be carried out for the major affective disorders as discussed here. We present here five groupings of genes implicated by neuropharmacological and other evidence, which suggest 252 candidate genes worth examining. Inexhaustiveness of gene interrogation would apply to many studies in which only one polymorphism per gene is analyzed. In contrast to whole-genome association studies, a study of a limited number of candidate genes can readily exploit information on genomic sequence variations obtained from databases and/or resequencing, and has an advantage of not having the complication of an extremely stringent statistical criterion for association. Molecular Psychiatry (2005) 10, 719-740.
Identifying susceptibility genes has long been challenging in studies of major affective disorders, as well as in other common complex diseases such as schizophrenia, asthma, diabetes, and cardiovascular diseases. Association study, which typically examines differences in allele frequency of a genetic marker between cases (affecteds) and controls, remains a major approach of disease gene mapping, and has been employed to examine possible roles of candidate genes in the etiology of a disease of interest.
Genomewide linkage analysis, in contrast, does not limit itself to a particular genomic region, apparently avoiding the risk of overlooking any genes with poor or even no information on biological functions. For more than two decades, linkage mapping has proven to be remarkably effective to guide researchers to numerous disease genes, each predisposing to a Mendelian trait. Also, development of computer algorithms for model-free linkage analysis has considerably facilitated appropriate genetic dissections of complex phenotypes with unknown mode of inheritance. In studies of major psychiatric illnesses, evidence of linkage has led to the detection of associations of specific genes with illness: dysbindin 1 (DTNBP1) 1 on chromosome 6p and neuregulin 1 (NRG1) 2 on 8p for schizophrenia, and G72/G30 on 13q for both schizophrenia 3 and bipolar disorder. 4 These genes have been demonstrated to be associated with schizophrenia and/or bipolar disorder in multiple independent data sets. [5] [6] [7] [8] However, model-free linkage analysis is unlikely to detect genes with very weak effects (modest increase in probability of illness, given the associated allele). This has led to a resurgence of association analysis because of its much higher statistical power, particularly in the studies of complex diseases, where multiple genes are considered to exert weak effect along with environmental factors. 9 Candidate gene association studies have historically been plagued by nonreplication. A recent meta-analysis of genes that had a large number of association studies emphasized possible contribution of false-negative underpowered studies to inconsistent results, and suggested consistent weak effects of the genes for serotonin receptor 2A (HTR2A) and dopamine receptor D3 (DRD3) on susceptibility to schizophrenia. 10 Thus, inconsistencies among reports may be consequences of what previous studies have failed to address. Until recently, it has only been feasible to interrogate a few genes in particular systems, and these interrogations have often been limited to very few polymorphisms in a limited number of subjects, because of limitations in the costs of genotyping, and in the knowledge of the human genome. Advances in genomics and bioinformatics, in high-throughput genotyping, in statistical analysis, and in the availability of large samples of patients with well-defined phenotypes, as well as comparable numbers of matched controls, can be expected to enhance the likelihood of detection of valid associations.
What remains as the most serious concern about the paradigm of candidate gene association study is its 'incompleteness' resulting from ad hoc selection of candidate genes. A priori hypotheses have to be made on the primary cause of the disease being studied, when starting a candidate gene study. For many years, genes have usually been tested in a 'one by one' manner for association with major affective disorders, primarily bipolar illness. However, it is also conceivable that not individual genes but abnormalities in several genes within a system or in several neuronal, neural, or hormonal systems are implicated in the functional hypotheses for etiology of affective disorders. Analysis of entire systems examining a same sample set has only rarely been undertaken, 11, 12 and examples of definitive success have yet to be seen. At this time, analysis of a well-chosen and comprehensive set of candidate genes, with the support of informatics analysis of the genomic structure of each gene, may yield successful detection of specific genes and pathways associated with illness.
In the following sections, we first discuss the advantage of a hypothesis-based systematic association study on a limited number of candidate genes in contrast to the whole-genome association study, and subsequently demonstrate that, in the case of affective disorders, compilation of candidate genes pertinent to each major neurobiological system suggested for susceptibility can be reasonably carried out. The idea of testing systems can be generalized to studies of other common complex diseases.
Systematic candidate gene study vs whole-genome association study
Association studies are intended to capture linkage disequilibrium (LD) between genotyped markers and a disease causal variant, including when the marker being genotyped happens to be exactly the causal variant. Recent studies have revealed that chromosomal segments, spanning a few to hundreds of kilobases, can often be represented by only a few haplotypes because of strong underlying LD that associates specific alleles at each polymorphic site in the segment. Such a segment is called a 'haplotype block' and the analysis of a block can be achieved by typing a small set of SNPs (haplotype tag SNPs or htSNPs) that are most informative for discriminating haplotypes. 13 16 even genotyping with a marker density obtained by resequencing would capture only up to 71% of the entire genome as blocks. Besides, gene conversion, which is not incorporated into this model, seems to have generated discrepancies between haplotype block fractions observed in actual data and predicted by simulations. Gene conversion can give rise to a 'hole' in an LD or a haplotype block, and a susceptibility variant in such a hole is likely to be overlooked. Secondly, even when a haplotype block is evident, it is unclear if markers from the databases capture sufficient haplotype diversity. For example, a haplotype with an estimated frequency of 45% may really be a group of three haplotypes each with a frequency of 15%. This loss of information can substantially reduce the power of detecting association depending on the frequency of a causal variant. Selecting the most informative markers not depending on the haplotype block model, as suggested in Carlson et al, 17 would considerably circumvent these problems. Resequencing of genomic regions of interest will also be necessary (see Electronic-Database Information for current examples). From the viewpoint of the number of SNPs to be genotyped, these approaches look feasible for a study of a limited number of candidate genes, but not for whole-genome LD mapping or for its gene-focused form. 9, 18, 19 Since the prior probability of association for a biologic candidate gene can be expected to be considerably higher than that for a gene randomly picked up from the genome, candidate gene approach may benefit from increased statistical power by analysis controlling 'false discovery rate'. 20 Even in the conventional statistical tests (eg Bonferroni procedure) for multiple hypotheses, which control overall type I error rate, the study of limited number of candidates derived from a few hypotheses would not suffer from the complication of a very stringent statistical criterion for association, because the number of markers would be less than in a whole-genome LD mapping. Also, a method has recently been developed to detect a set of associated genes, which may statistically interact with each other. 21 Interpretation of results of this analysis can be more Genetic tests of systems in affective disorders E Hattori et al straightforward when we study multiple genes with known biologic functions. Thus, whole-genome association study does not replace the candidate gene approach using a sufficient number of informative markers, particularly when we are anxious about missing associations.
Genetic testing of functional systems (pathways) in major affective disorders
Since the first monoamine hypothesis (Figure 1 ) of depression, based on biochemical pharmacology of antidepressants and reserpine, numerous hypotheses of dysregulation of functional systems in mood disorders have been suggested, but so far no consensus has been reached on any primary molecular mechanism underlying mood disorder susceptibility. Nonetheless, the choice of several systems (Table 1) over others for intensive genetic study can be supported by their relevance to clinical features as well as by accumulated neurobiological and neuropharmacological findings. Phenotypic subclasses of the entire spectrum of affective disorders may have different associations with the systems in Table 1 . However, we need not assume too much about a specific relationship between systems and subclasses. When samples from different types of affective disorders with abundant clinical records are available, it may be more reasonable to conduct genetic analyses on numerous phenotypic variables after completion of genotyping. Such an approach has successfully been employed in detecting association between the PDE4D gene and ischemic type stroke in the analysis of all the samples from broadly defined common forms of stroke. 22 The first step of compiling candidate genes in a given functional hypothesis is to list genes involved in pathways which represent that hypothesis. GO and KEGG databases, for example (see Electronic-Database Information), help overview a set of genes involved in a particular intracellular pathway. To obtain information on genetic components specifically relevant to the phenotypes of interest, intensive literature survey or review is required. There have been a huge number of reports on specific proteins (sometimes specific subtypes) altered in post-mortem brains from bipolar disorder subjects or in brains from rodents treated with mood stabilizers. Also, animal models and systematic expression analyses by microarray or differential display assay provide information on molecules relevant to mood disorders not only at the protein level but also at the gene expression level. Figure 1 Evolution of 'monoamine hypothesis'. A major hypothesis for the biology of depression was developed in the 1960s, initially proposing that depletion of norepinephrine (NE), and later proposing depletion of serotonin (5-HT) and dopamine (DA), underlie the illness. 100 This 'monoamine hypothesis' was proposed because of the clinical observation that depression often occurs in subjects taking reserpine, an antihypertensive agent, which depletes monoamines from the synaptic vesicles. Also, consistent with the hypothesis was that tricyclic antidepressants and MAO inhibitors were found to increase synaptic monoamine concentrations. The hypothesis was later modified to include alterations of monoamine receptor properties so that it would encompass an explanation for the time (usually days to weeks) required for an antidepressant to take clinical effect despite its immediate action to elevate synaptic monoamine levels. 101, 102 However, either the original or modified form of hypothesis has not been definitively demonstrated so far. Involvement of postsynaptic signaling is now of interest to researchers. A diagram for NE neurotransmission is shown as an example. The postsynaptic receptors for NE are coupled to guanine nucleotide binding proteins (G proteins), which transduce neurotransmitter stimulation to second messenger signaling systems such as cAMP and phosphoinositide pathways. Now that numerous components in the NE neurotransmission system have been identified, including metabolic enzymes, receptors, transporters, and postsynaptic signaling (eg one or more subtypes of G proteins, protein kinase A, protein kinase C, calcium/calmodulin-dependent protein kinases), emphasis is being placed on the broader view of dysregulation in the entire system, 103 taking interactions of each component into account. Components are presented at the gene level in Table 2 . NE: norepinephrine; VMAT: vesicular monoamine transporters; MAO: monoamine oxidases, COMT: catechol-O-methyltransferase; ax-AR: axadrenerigc receptors; b1-AR: beta-1-adrenergic receptor; G: G proteins; AC: adenylate cyclases; PL: phospholipases; PKA: cAMP-dependent protein kinases; PKC: calciumdependent protein kinases; CREB: cAMP-responsive element binding protein; NET: norepinephrine transporter; DAT: dopamine transporter.
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Genes repeatedly reported to be associated with the phenotype of interest should be included. In addition, databases being developed (see GEO and WebQTL in Electronic-Database Information) allow for retrieving and analyzing gene expression data according to researchers' particular interest, and may contribute to more extensive compilation of candidate genes in near future.
There are problems in this approach, though. First, manual literature mining on which compilation of candidate genes mostly depends is a tedious procedure. Secondly, there is no completely objective criterion to determine genes representing each hypothesis. Microarray studies may provide valid quantitative data on difference in expression level of each gene between bipolar and healthy subjects or between disease model and wild-type animals. However, such data may represent secondary effects of illness or treatment, or species-specific effects. Although a genetic association strategy can resolve this possibility, it will be a very small fraction of differentially expressed genes that directly affect susceptibility to the illness.
Despite these challenges, we have carried out compilation of a list of candidate genes pertinent to major hypotheses of major affective disorders (Table 2) .
Neurotransmission systems
The monoamine (adrenergic, dopaminergic, and serotonergic) neurotransmission systems, which were the first to be hypothesized as systems whose derangements cause mood disorders, are offered here as a detailed example of candidate gene selection in the neurotransmission systems (see also Figure 1 ).
The genes for tyrosine hydroxylase (TH), which is a rate-limiting enzyme for dopamine and norepinephrine synthesis, and serotonin transporter (SLC6A4), which is a pump molecule for reuptake of synaptic serotonin into the presynaptic nerve terminal, have been among the most frequently studied candidates for affective disorders. Abnormalities of these genes can lead to decreased vesicular or synaptic monoamine levels as predicted by the original monoamine hypothesis. However, association has not been consistently replicated for any genes for synaptic components including TH and SLC6A4. 23 Genes for synaptic components of monoamine systems, nonetheless, still deserve genetic analysis, given the possible insufficiency of sample size and number of markers analyzed in the previous studies. In the presynaptic nerve terminal, these include genes for synthetic enzymes (eg TH, DBH, DDC), synaptic vesicle monoamine transporters (SLC18A1 and SLC18A2), and reuptake transporters (SLC6A2, SLC6A3, and SLC6A4), with many being shared between the three neurotransmitters ( Table 2) . Monoamines bind to pre-and postsynaptic receptors, of which numerous subtypes have been found so far. The list includes seven genes coding for adrenergic receptors, five for dopaminergic receptors, and 14 for serotonergic receptors, omitting those with limited roles in the brain such as beta-2-adrenergic receptor (ADRB2). Genes for catabolic enzymes bound to postsynaptic membrane (monoamine oxidases (MAOA and MAOB) and catechol-O-methyltransferase (COMT)) have also been included in the list.
Abnormality in postsynaptic signaling in bipolar disorder was first proposed in the phosphoinositide cycle because it is affected by lithium administration. 24, 25 Myo-inositol monophosphatase is inhibited Parkinson's disease genes (eg PARK2, SCNA, UCHL1) Schizophrenia-related genes (eg NRG1, DTPN1) and genes in the myelination system (eg MBP, MOG, NRG1)
Genetic tests of systems in affective disorders E Hattori et al Table 2 Candidate genes pertinent to each putative pathological system: 1. Neurotransmission; 2. A neuroendocrine system; 3. Neurotrophic/growth factor systems; ( 26, 27 Another gene in this pathway, phosphoinositide-3-kinase class 3 (PIK3C3), was recently reported to be associated with bipolar disorder and schizophrenia. 28 Calcium signaling is closely linked to the phosphoinositide pathway, and expression of protein kinase C subtypes (PRKCA and PRKCE) and its substrate myristoylated alanine-rich protein kinase C (MARCKS) are reduced in the rat brain after chronic treatment with lithium. 29 Monoamine neurotransmitter receptors, such as alpha2 and beta-1-adrenergic receptors, are coupled to G proteins, which, upon stimulation, activate enzymes in the cAMP-signaling pathway. The gene for regulator of G-protein signaling 4 (RGS4) was initially brought into attention by a microarray study and recently reported to be associated with schizophrenia. 30 Selecting candidates based on expression data also led to the detection of associations of Gprotein-coupled receptor kinase3 (GRK3) 31 and other promising gene 32 with bipolar disorder. Altered expression level of G protein AS and AI2 subunits (GNAS, GNAI2) in the post-mortem brains from bipolar or lithium receiving subjects has also been reported, 33 although variants in the former gene are not apparently associated with bipolar disorder. 34 Recent animal studies demonstrated that chronic administration of antidepressants induces elevation of cAMP-responsive element binding protein gene (CREB1) expression- 35 and cAMP-responsive element modulator (CREM)-deficient mice showed emotional and behavioral changes. 36 Also, chronic antidepressant administration increases cAMP phosphodiesterase (PDE4A and PDE4B) expression in rat frontal cortex. 37 A phosphodiesterase inhibitor, rolipram, has been reported to have an antidepressive effect. 38 Further, abnormalities of molecules that overarch multiple intracellular signaling pathways (eg calcium/ calmodulin-dependent protein kinase II alpha (CAM-K2A), 39, 40 DARPP-32 (PPP1R1B), 41 and v-akt murine thymoma viral oncogene homologs (AKT1), 42, 43 are also suggested in psychiatric illnesses.
Roles of other neurotransmission systems including cholinergic, amino acid (glutamate and GABA) and peptidergic neurotransmission in bipolar disorder or related physiological functions such as appetite and anxiety are also supported by neuropharmacological findings, [44] [45] [46] [47] [48] although not detailed here.
A neuroendocrine system
The hypothalamic-pituitary-adrenocortical (HPA) axis has a long history as a stress-response pathway and has been repeatedly suggested to play a role in major depressive disorder. 49 A recent hypothesis that elevated levels of cortisol in depressed patients may contribute to neuronal death and to reduced dendritic arborizations in hippocampus [50] [51] [52] seems to have a potential for elucidating the etiology of mood disorder. This hypothesis is consistent with the The total number of candidate genes: 257; total genomic size: 26 620 628 bp.
a When a gene has not intensively been studied despite its putative key biologic role in one of the pathways, it may lack a reference. Conversely, when numerous studies have been conducted, review articles, meta-analyses, and large-scale studies are preferentially given.
Genetic tests of systems in affective disorders E Hattori et al previous neuroimaging findings reporting reductions of hippocampal volume in some mood disorder subjects. 53, 54 Obvious candidates based on these formulations are genes encoding peptide hormones (proopiomelanocortin (POMC) and corticotrophin-releasing hormone precursor (CRH)) and their receptors (MC2R, MC4R, CRHR1, and CRHR2). In addition, glucocorticoid receptor (NR3C1), which binds to glucocorticoids and then enters the nucleus to enhance or inhibit gene expression by direct binding to glucocorticoid response elements or by interactions with other transcriptional factors such as CREB, can be considered an important signaling component. Other candidates include genes for heat-shock proteins such as HSPA5, which associate with the glucocorticoid receptor as chaperones, multidrug-resistant protein 1 (ABCB1), which pumps out cortisol from the cell, 55 and 11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1), which metabolizes cortisol. 56 
Neurotrophic factor systems
There has been growing evidence supporting roles of neurotrophic factors and growth factors, which regulate neuronal growth, development, survival, and plasticity, in mood disorders. The gene for brain-derived neurotrophic factor (BDNF), which is involved in neuronal survival and arborization in hippocampus, is an unusually promising candidate. The expression of BDNF is decreased by stress and glucocorticoids 57 and is increased by chronic antidepressant or electroconvulsive treatment in rat hippocampus. 58, 59 Association between BDNF and bipolar disorder has been replicated in independent pedigree samples. 60, 61 Also, the gene for insulin-like growth factor I (IGF1) would be worth studying based on its role in neurogenesis and reported altered expression level in the brains of metamphetaminetreated rats. 62 Recently, a requirement was demonstrated for hippocampal neurogenesis for behavioral effects of antidepressants, consistent with importance of genes involved in neurogenesis in studies of depression. 63 As in the neurotransmission systems and HPA axis, genes for molecular components of the neurotrophic factor system have not been systematically studied for association with bipolar disorder. Genes such as NTRK2 and NTRK3 coding for neurotrophic factor receptors collectively called Trk are candidates as well as genes for ligands. Among the several intracellular cascade systems activated upon Trk stimulation are phosphoinositide signaling and protein kinase C pathway, whose components are shared with neurotransmission systems described above. It may be challenging to select candidates from the mitogen-activated protein (MAP) kinase cascade, another intracellular signaling pathway downstream of Trk, because of the large number of subtypes for each protein. However, an expression study on PC12 cells differentiated by nerve growth factor (NGF)
showed that lithium administration altered expression of two genes (MAP2K2 and MAPK1) encoding kinases of this pathway. 64 
Circadian rhythm
Abnormalities in circadian rhythm are found in seasonal affective disorder as well as in a fraction of patients with major depression. The fact that interventions on circadian rhythm such as light therapy and sleep deprivation can improve the symptoms of depression or provoke mania might be indicative of an etiological role of this system. 65 The mammalian circadian pacemaker is located within the suprachiasmatic nucleus (SCN) in the hypothalamus. 'Clock genes' (eg CLOCK, ARNTL (BMAL1), ARNTL2 (BMAL2), PER1, PER2, and PER3) play crucial roles in generating and regulating circadian rhythm, and mutations of these genes have already been reported to cause abnormal circadian locomotion in rodents. In the past several years, many clock genes have been identified in various species such as Drosophilae, fungi, and rodents. As human counterparts or homologues have already described for most clock genes, 66 the circadian rhythm system is amenable to genetic dissection.
Although the clock genes are probably the first candidates to be studied in the circadian rhythm system, it is noteworthy that these gene loci did not show major effect on strain variability in mouse circadian behavior in a genomewide analysis. 67 Studying nonclock genes with suggested roles in circadian rhythm would also be important. Since the SCN can be entrained to light/dark cycle, genes encoding components involved in photoreception in the retinohypothalamic tract are intriguing candidates. For example, pituitary adenylate cyclaseactivating polypeptide (ADCYAP1) is a major neurotransmitter of this tract as well as glutamate. 68 Lack of either of its receptor genes, ADCYAP1R1 or VIPR2, leads to abnormal circadian phenotype in rodents. 69 In addition, since diurnal rhythmicity in physiological functions and behaviors is eventually affected in mood disorder, output pathways from the SCN, including pineal melatonin secretion, 70, 71 cannot be omitted. Recently, transforming growth factor-a (TGFA) 72 and prokineticin 2 (PROK2), 73 substances secreted from the SCN to adjacent hypothalamic areas, have been reported to regulate behavioral circadian rhythm in mice.
Systems implicated in Parkinson's disease and schizophrenia
Other CNS diseases may also provide clues for susceptibility genes for mood disorders, if they share etiological mechanisms with mood disorders. Symptoms of depression occur in approximately half of the subjects with Parkinson's disease. Although neuropathological changes characteristic of Parkinson's (PARKIN), UCHL1) . 76 Several other components that play crucial roles in this pathway have also been reported; for example, Parkin-associated endothelin receptor-like receptor (Pael-R) 77 and CDCrel-1 (PNUTL1) 78 suggested for one of the substrates for PARKIN-mediated ubiquitination. Also, a protein called carboxy-terminus of Hsp70p-interacting protein (CHIP) is known to modulate the function of PARKIN. 79 Also, the hypothesis that one subclass of major affective disorders shares susceptibility genes in common with schizophrenia is particularly promising. Genetic epidemiology has provided evidence for this overlap, primarily in family studies. Gershon et al observed an excess of major depression and schizoaffective disorder in the relatives of both mood disorder and schizophrenia probands. 80, 81 The excess of major depression in relatives of both mood disorders and schizophrenia has been a consistent finding. 82 Studies from three data sets have addressed the issue of psychotic mood disorder/schizophrenia overlap. Two of the data sets found elevated rates of psychotic mood disorder in relatives of schizophrenic probands, and vice versa;
83-86 the third also suggested shared liability. 87 In addition, some twin studies have found evidence of shared heritability between psychotic mood disorder and schizophrenia. 88, 89 Further, linkage studies of bipolar illness and schizophrenia have implicated overlapping chromosomal regions, including 10p12-13, 13q31-33, 18p11.2, and 22q11-13, 90, 91 although not all analyses agree. 92 There has been considerable progress in identifying genes associated with schizophrenia, particularly in chromosomal regions where evidence of linkage was suggested. Among them, the G72/G30 gene locus on 13q33 has been demonstrated to be associated with both schizophrenia and bipolar disorder. 3, 4, [6] [7] [8] The notion of shared susceptibility gene is also supported by a very recent association study on DISC1 gene. 93 Other schizophrenia genes such as NRG1 and DTNBP might also be worth studying for possible association with mood disorders. In addition, a recent study has demonstrated convergent expression alterations of genes involved in myelination in both schizophrenia and bipolar disorder. 94 Such genes would be good candidates for susceptibility genes shared by major psychiatric illnesses. Studying these genes implicated in the pathophysiology of schizophrenia may contribute to eventual reconstruction of the current diagnostic nosology, and to identification of new molecular targets with broad therapeutic spectra.
Prioritizing candidate genes by quantitative trait loci (QTL) analysis
Combining microarray gene expression data and gene mapping methods to identify genetic determinants of gene expression (expression phenotypes) has recently been applied in several species, including mouse and human. [95] [96] [97] This has resulted in the successful identification of QTLs, which control the baseline expression levels of some genes. We have used this approach to identify regulators of the expression of the candidate genes we compiled, in the adult BXD recombinant inbred mice. We decided to use QTL mapping data in mouse instead of human, because the only available human QTL mapping results are from lymphoblast cell lines, and it has been shown in mouse that QTLs in brain and hematopoietic stem cells differ greatly. 98 Interval mappings were performed at the WebQTL site (see Electronic-Database Information), using UTHSC Brain mRNA U74Av2 (Mar04) RMA Orig database. QTL with an empirical genome-wide P-value less than 0.05 was detected for six genes, namely HTR2B, HTR4, GRIN2B, PRKCE, PER3, and BCL2.
We then determined if any of the QTLs is in syntenic regions to human bipolar linkage findings. If a cis-acting QTL, for which the QTL is in the target gene itself, overlaps with bipolar linkage, the target gene itself merits testing in association studies as positional candidate for bipolar linkage. If the overlapping QTL is a trans-acting QTL, the regulator at the QTL is a new candidate gene for association study. Thus, linkage results to gene expression may point to new candidate genes and underlying regulatory pathways for the bipolar linkage. We found that two QTLs overlap with bipolar linkage regions. A translinked QTL for two genes, HTR4 and BCL2, is mapped to the same region in mouse genome, and may thus represent a single linkage. This trans-linked QTL for the two genes can be divided into four segments, three of which are in syntenic regions to bipolar linkage findings at 2q, 92 6q, 99 and 10q, 92 respectively. In addition, a cis-QTL for the gene PER3 is in syntenic region to bipolar linkage finding at 1p. 92 This suggests that PER3 is a good candidate for this bipolar linkage. With the identification of more bipolar linkages and the improvement of QTL mapping methods, the list of genes with QTLs overlapping with bipolar linkage will certainly grow.
Requirements for implementation of the systems genetic approach and future directions
The approach being suggested would benefit from the feasibility of much denser genotyping compared to the whole-genome LD mapping. It requires collection of information on functional importance of polymorphic markers, as well as positions, flanking sequences, validation status, and allele frequencies. Since the information is scattered on multiple webbased databases such as those from UCSC Genome Genetic tests of systems in affective disorders E Hattori et al Bioinformatics, dbSNP, HapMap, and SNP Consortium (see Electronic-Database Information), manual mining of information can be tedious and sometimes infeasible. What is needed is a sophisticated informatics system facilitating compilation of pieces of information from different resources into a single platform. We might further assign priority of genotyping to each polymorphism according to its potential functional effect and the degree of LD with other polymorphisms.
Genotype data obtained by the study of multiple genes in a biologic system may provide a set of multiple susceptibility genes either through conventional association analyses or through multilocus association analyses such as the one developed by Hoh et al. 21 Although the latter may provide a list of susceptibility genes, in which some of them are exerting interacting effects, we further need computational modeling, which allows for systems analysis describing specific relationships between genes and clinical features. This would provide a basis for putting genetic results back into biological and clinical context. The systems listed in Table 1 are considered more complex in reality than described above, and it is also possible that interactions between systems rather than within a system increase the risk for major affective disorders. For example, a suggested integral model views multiple systems from a single perspective of neuronal death/survival. Hyperfunction of glutamatergic neurotransmission and HPA axis can lead to neuronal death, whereas adrenergic/serotonergic neurotransmission and neurotrophic factors favor neuronal survival/arborization or neurogenesis, with each system interacting with several others. [50] [51] [52] The hypothesis-based study described so far is expected to increase the likelihood of obtaining outputs that can be reasonably interpreted through the current biological and epidemiological knowledge of major affective disorders. The systems functioning conclusions from the genetic outputs, although, would not necessarily be completely consistent with the current hypothesis-based systems. The biological meaning of the genetic outputs could be tested by further research designs such as multiple
